Kelliher Mike
Known title: See RemarksCIK: 0001987188
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 3,104 | $12K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,652 | $10K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,002 | $8K | 8/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,900 | $18K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,870 | $12K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,478 | $16K | 5/21/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 8,434 | $49K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,159 | $7K | 2/20/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 2 | $11 | 2/20/2026 | View on chart |
| ARDX | ▲ Buy | Grant | 103,080 | $0 | 1/23/2026 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,560 | $31K | 11/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,417 | $32K | 8/21/2025 | View on chart |
| ARDX | ▼ Sell | Open Market | 14,522 | $59K | 5/20/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 136,680 | $0 | 2/25/2025 | View on chart |
| ARDX | ▲ Buy | Grant | 160,000 | $0 | 3/25/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.